S. Y. Tong, J. S. Davis, E. Eichenberger, T. L. Holland, and F. Vg, Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management, Clin Microbiol Rev, vol.28, issue.3, pp.603-61, 2015.

C. J. Kaandorp, P. Krijnen, H. J. Moens, J. D. Habbema, and D. Van-schaardenburg, The outcome of bacterial arthritis: a prospective community-based study, Arthritis Rheum, vol.40, issue.5, pp.884-92, 1997.

M. Na, A. Jarneborn, A. Ali, A. Welin, M. Magnusson et al., Deficiency of the complement component 3 but not factor B aggravates Staphylococcus aureus septic arthritis in mice, Infect Immun, vol.84, issue.4, pp.930-939, 2016.

M. Verdrengh and A. Tarkowski, Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus, Infect Immun, vol.65, issue.7, pp.2517-2538, 1997.

M. Verdrengh and A. Tarkowski, Role of macrophages in Staphylococcus aureusinduced arthritis and sepsis, Arthritis Rheum, vol.43, issue.10, pp.2276-82, 2000.

A. Abdelnour, T. Bremell, R. Holmdahl, and A. Tarkowski, Clonal expansion of T lymphocytes causes arthritis and mortality in mice infected with toxic shock syndrome toxin-1-producing staphylococci, Eur J Immunol, vol.24, issue.5, pp.1161-1167, 1994.

J. B. Kolata, I. Kuhbandner, C. Link, N. Normann, C. H. Vu et al., The fall of a dogma? Unexpected high T-cell memory response to Staphylococcus aureus in humans, J Infect Dis, vol.212, issue.5, pp.830-838, 2015.

J. F. Bermejo-martin, D. Andaluz-ojeda, R. Almansa, F. Gandia, J. I. Gomez-herreras et al., Defining immunological dysfunction in sepsis: a requisite tool for precision medicine, J Inf Secur, vol.72, issue.5, pp.525-561, 2016.

C. Tebartz, S. A. Horst, T. Sparwasser, J. Huehn, A. Beineke et al., A major role for myeloid-derived suppressor cells and a minor role for regulatory T cells in immunosuppression during Staphylococcus aureus infection, J Immunol, vol.194, issue.3, pp.1100-1111, 2015.

C. L. Bennett, J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson et al., The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3, Nat Genet, vol.27, issue.1, pp.20-21, 2001.

J. H. Buckner, Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases, Nat Rev Immunol, vol.10, issue.12, pp.849-59, 2010.

J. Kim, K. Lahl, S. Hori, and C. Loddenkemper, Chaudhry a, deRoos P, Rudensky a, Sparwasser T: cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice, J Immunol, vol.183, issue.12, pp.7631-7635, 2009.

S. A. Long and J. H. Buckner, CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game, J Immunol, vol.187, issue.5, pp.2061-2067, 2011.

S. Sakaguchi, M. Miyara, C. M. Costantino, and D. A. Hafler, FOXP3+ regulatory T cells in the human immune system, Nat Rev Immunol, vol.10, issue.7, pp.490-500, 2010.

Y. Tanaka, Clinical immunity in bone and joints, J Bone Miner Metab, vol.37, issue.1, pp.2-8, 2019.

L. Barron, H. Dooms, K. K. Hoyer, W. Kuswanto, J. Hofmann et al., Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells, J Immunol, vol.185, issue.11, pp.6426-6456, 2010.

A. K. Abbas, E. R. Trotta, D. Simeonov, A. Marson, and J. B. , Revisiting IL-2: Biology and therapeutic prospects, Sci Immunol, vol.3, 2018.

D. Klatzmann and A. K. Abbas, The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases, Nat Rev Immunol, vol.15, issue.5, pp.283-94, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01617541

A. Hartemann, G. Bensimon, C. A. Payan, S. Jacqueminet, O. Bourron et al., Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol, vol.1, issue.4, pp.295-305, 2013.

J. Koreth, K. Matsuoka, H. T. Kim, S. M. Mcdonough, B. Bindra et al., Interleukin-2 and regulatory T cells in graft-versus-host disease, N Engl J Med, vol.365, issue.22, pp.2055-66, 2011.

M. Rosenzwajg, G. Churlaud, R. Mallone, A. Six, N. Derian et al., Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients, J Autoimmun, vol.58, pp.48-58, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01112156

D. Saadoun, M. Rosenzwajg, F. Joly, A. Six, F. Carrat et al., Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis, N Engl J Med, vol.365, issue.22, pp.2067-77, 2011.

M. Rosenzwajg, R. Lorenzon, P. Cacoub, H. P. Pham, F. Pitoiset et al., Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial, Ann Rheum Dis, vol.78, issue.2, pp.209-226, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01980090

O. Goldmann and E. Medina, Staphylococcus aureus strategies to evade the host acquired immune response, Int J Med Microbio, vol.308, issue.6, pp.625-655, 2017.

T. Bremell, S. Lange, L. Svensson, E. Jennische, K. Grondahl et al., Outbreak of spontaneous staphylococcal arthritis and osteitis in mice, Arthritis Rheum, vol.33, pp.1739-1783, 1990.

V. Jimenez, E. Ayuso, C. Mallol, J. Agudo, A. Casellas et al., In vivo genetic engineering of murine pancreatic beta cells mediated by single-stranded adeno-associated viral vectors of serotypes 6, 8 and 9, Diabetologia, vol.54, issue.5, pp.1075-86, 2011.

A. Ali, A. Welin, J. C. Schwarze, M. N. Svensson, M. Na et al., CTLA4 immunoglobulin but not anti-tumor necrosis factor therapy promotes staphylococcal septic arthritis in mice, J Infect Dis, vol.212, issue.8, pp.1308-1324, 2015.

Y. Grinberg-bleyer, A. Baeyens, S. You, R. Elhage, G. Fourcade et al., IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells, J Exp Med, vol.207, issue.9, pp.1871-1879, 2010.

Y. Fei, W. Wang, J. Kwiecinski, E. Josefsson, R. Pullerits et al., The combination of a tumor necrosis factor inhibitor and antibiotic alleviates staphylococcal arthritis and sepsis in mice, J Infect Dis, vol.204, issue.3, pp.348-57, 2011.

F. Fatima, Y. Fei, A. A. Mohammad, M. Erlandsson, M. C. Bokarewa et al., Radiological features of experimental staphylococcal septic arthritis by micro computed tomography scan, PLoS One, vol.12, issue.2, p.171222, 2017.

G. Churlaud, V. Jimenez, J. Ruberte, A. Zin, M. Fourcade et al., Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer, Clin Immunol, vol.151, issue.2, pp.114-140, 2014.

T. Bremell, A. Abdelnour, and A. Tarkowski, Histopathological and serological progression of experimental Staphylococcus aureus arthritis, Infect Immun, vol.60, issue.7, pp.2976-85, 1992.

V. C. Weston, A. C. Jones, N. Bradbury, F. Fawthrop, and M. Doherty, Clinical features and outcome of septic arthritis in a single UK Health District, 1982.

, Ann Rheum Dis, vol.58, issue.4, pp.214-223, 1999.

T. R. Malek, The biology of interleukin-2, Annu Rev Immunol, vol.26, pp.453-79, 2008.

N. Nilsson, T. Bremell, A. Tarkowski, and H. Carlsten, Protective role of NK1.1+ cells in experimental Staphylococcus aureus arthritis, Clin Exp Immunol, vol.117, issue.1, pp.63-72, 1999.

I. Gjertsson, O. H. Hultgren, M. Stenson, R. Holmdahl, and A. Tarkowski, Are B lymphocytes of importance in severe Staphylococcus aureus infections?, Infect Immun, vol.68, issue.5, pp.2431-2435, 2000.

M. Hashizume, N. Hayakawa, and M. Mihara, IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17, Rheumatology (Oxford), vol.47, issue.11, pp.1635-1675, 2008.

L. Henningsson, P. Jirholt, C. Lindholm, T. Eneljung, E. Silverpil et al., Interleukin-17A during local and systemic Staphylococcus aureus-induced arthritis in mice, Infect Immun, vol.78, issue.9, pp.3783-90, 2010.

P. Palmqvist, E. Persson, H. H. Conaway, and U. H. Lerner, IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae, J Immunol, vol.169, issue.6, pp.3353-62, 2002.

Y. H. Zhang, A. Heulsmann, M. M. Tondravi, A. Mukherjee, and Y. Abu-amer, Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways, J Biol Chem, vol.276, issue.1, pp.563-571, 2001.

I. Gjertsson, O. H. Hultgren, and A. Tarkowski, Interleukin-10 ameliorates the outcome of Staphylococcus aureus arthritis by promoting bacterial clearance, Clin Exp Immunol, vol.130, issue.3, pp.409-423, 2002.

C. Bachert, G. Holtappels, M. Merabishvili, T. Meyer, A. Murr et al., Staphylococcus aureus controls interleukin-5 release in upper airway inflammation, J Proteome, vol.180, pp.53-60, 2018.

P. A. Krishack, T. J. Louviere, T. S. Decker, T. G. Kuzel, J. A. Greenberg et al., Protection against Staphylococcus aureus bacteremia-induced mortality depends on ILC2s and eosinophils, JCI Insight, vol.4, 2019.

J. He, X. Zhang, Y. Wei, X. Sun, Y. Chen et al., Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus, Nat Med, vol.22, issue.9, pp.991-994, 2016.

C. Von-spee-mayer, E. Siegert, D. Abdirama, A. Rose, A. Klaus et al., Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus, Ann Rheum Dis, vol.75, issue.7, pp.1407-1422, 2016.

K. Matsuoka, J. Koreth, H. T. Kim, G. Bascug, S. Mcdonough et al., Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease, Sci Transl Med, vol.5, issue.179, pp.179-143, 2013.

T. Dietrich, T. Hucko, C. Schneemann, M. Neumann, A. Menrad et al., Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells, Atherosclerosis, vol.220, issue.2, pp.329-365, 2012.

T. N. Dinh, T. S. Kyaw, P. Kanellakis, K. To, P. Tipping et al., Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis, Circulation, vol.126, issue.10, pp.1256-66, 2012.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations